TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 2251-2258

  Wong, Carmen P ^a   Okada, Craig Y ^b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD40 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOCYANIN; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 12; OKT 8; QS 21; RECEPTOR ANTIBODY; SYNTEX ADJUVANT FORMULATION 1; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL TRANSFER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; T CELL LYMPHOMA; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SAPONINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033557726     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. George, A. J., S. G. Folkard, T. J. Hamblin, and F. K. Stevenson. 1988. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 141:2168.
2. Campbell, M. J. W. Carroll, S. Kon, K. Thielemans, J. B. Rothbard, S. Levy, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139:2825.
3. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145:1029.
4. Dyke, R. J., H. McBride, A. J. George, T. J. Hamblin, and F. K. Stevenson. 1991. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell Immunol. 132:70.
5. Hsu, F. J., Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. TaidiE. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
6. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotypic vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89:3129.
7. Kwak, L. W., M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med 327:1209.
8. Okada, C. Y., C. P. Wong, D. W. Denney, and R. Levy. 1997. TCR vaccines for active immunotherapy of T cell malignancies. J. Immunol. 159:5516.
9. Vandenbark, A. A., G. A. Hashim, and H. Offner. 1996. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J. Neurosci. Res. 43:391.
10. Kumar, V., E. Coulsell, B. Ober, G. Hubbard, E. Sercarz, and E. S. Ward. 1997. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: dose effects and involvement of both CD4 and CD8 T cells. J. Immunol. 159:5150.
11. Rosloniec, E. F., D. D. Brand, K. B. Whittington, J. M. Stuart, M. Ciubotaru, and E. S. Ward. 1995. Vaccination with a recombinant Vα domain of a TCR prevents the development of collagen-induced arthritis. J. Immunol. 155:4504.
12. Gold, D. P., K. Shroeder, A. Golding, S. W. Brostoff, and D. B. Wilson. 1997. T-cell receptor peptides as immunotherapy for autoimmune disease. Crit. Rev. Immunol. 17:507.
13. Gold, D. P., R. A. Smith, A. B. Golding, E. E. Morgan, T. Dafashy, J. Nelson, L. Smith, J. Diveley, J. A. Laxer, S. P. Richieri, D. J. Carlo, S. W. Brostoff, and D. B. Wilson. 1997. Results of a phase I clinical trial of a t-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV β 6 CDR2 peptide. J. Neuroimmunol. 76:29.
14. Vandenbark, A. A., G. Hashim, and H. Offner. 1989. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341:541.
15. Offner, H., G. A. Hashim, and A. A. Vandenbark. 1991. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251:430.
16. Lin, A. Y., B. Devaux, A. Green, C. Sagerstrom, J. F. Elliott, and M. M. Davis. 1990. Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science 249:677.
17. Chen, J., M. Trounstine, F. W. Alt, F. Young, C. Kurahara, J. F. Loring, and D. Huszar. 1993. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 5:647.
18. Allison, J. P., B. W. McIntyre, and D. Bloch. 1982. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J. Immunol. 129:2293.
19. Hyman, R., and V. Stallings. 1974. Complementation patterns of Thy-1 variants and evidence that antigen loss variants "pre-exist" in the parental population. J. Natl. Cancer Inst. 52:429.
20. Caras, I. W., M. A. Davitz, L. Rhee, G. Weddell, D. W. Martin, Jr., and V. Nussenzweig. 1987. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325:545.
21. Allison, A. C., and N. E. Byars. 1992. Syntex adjuvant formulation. Res. Immunol. 143:519.
22. + cytotoxic T lymphocyte responses. J. Immunol. 148:2357.
23. Kensil, C. R., J. Y. Wu, C. A. Anderson, D. A. Wheeler, and J. Amsden. 1998. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:41.
24. Kwak, L. W., H. A. Young, R. W. Pennington, and S. D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93:10972.
25. Macdonald, R. A., C. S. Hosking, and C. L. Jones. 1988. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 106:191.
26. Pullen, G. R., M. G. Fitzgerald, and C. S. Hosking. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86:83.
27. Luxton, R. W., and E. J. Thompson. 1990. Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis. J. Immunol. Methods 131:277.
28. Tao, M. H., and R. Levy. 1993. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755.
29. Syrengelas, A. D., T. T. Chen, and R. Levy. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2:1038.
30. Abrams, S. I., J. W. Hodge, J. P. McLaughlin, S. M. Steinberg, J. A. Kantor, and J. Schlom. 1997. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J. Immunother. 20:48.
31. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146:3235.
32. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
33. Qin, Z., G. Richter, T. Schuler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627.
34. Clynes, R., Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95:652.
35. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
36. Scott, P., and G. Trinchieri. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9:285.
37. Mendoza, R. B., M. J. Cantwell, and T. J. Kipps. 1997. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J. Immunol. 159:5777.
38. Kennedy, M. K., K. M. Mohler, K. D. Shanebeck, P. R. Baum, K. S. Picha, C. A. Otten-Evans, C. A. Janeway, Jr., and K. H. Grabstein. 1994. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur. J. Immunol. 24:116.
39. Maliszewski, C. R., K. Grabstein, W. C. Fanslow, R. Armitage, M. K. Spriggs, and T. A. Sato. 1993. Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines. Eur. J. Immunol. 23:1044.
40. Fanslow, W. C., K. N. Clifford, M. Seaman, M. R. Alderson, M. K. Spriggs, R. J. Armitage, and F. Ramsdell. 1994. Recombinant CD40 ligand exerts potent biologic effects on T cells. J. Immunol. 152:4262.
41. Sasaki, K., K. Hirata, K. Torimoto, T. Sakawaki, M. Nakamura, N. Sato, and K. Kikuchi. 1995. Macrophage colony stimulating factor inhibits experimental liver metastases from colon cancer. Anticancer Res. 15:1235.
42. Janson, C. H., M. J. Tehrani, H. Mellstedt, and H. Wigzell. 1989. Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia: characterization of the antibody, in vitro effector functions and results of therapy. Cancer Immunol. Immunother. 28:225.
43. Kanagawa, O. 1989. In vivo T cell tumor therapy with monoclonal antibody directed to the V β chain of T cell antigen receptor. J. Exp. Med. 170:1513.
44. Asano, M. S., and R. Ahmed. 1996. CD8 T cell memory in B cell-deficient mice. J. Exp. Med. 183:2165.
45. + T cells to protein antigens in vivo. J. Immunol. 155:3734.
46. Yang, X., and R. C. Brunham. 1998. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol. 161:1439.
47. Berger, C. L., B. J. Longley, S. Imaeda, I. Christensen, P. Heald, and R. L. Edelson. 1998. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the donotypic T-cell receptor. Int. J. Cancer 76:304.
48. Edelson, R. L. 1998. Cutaneous T-cell lymphoma: a model for selective immunotherapy. Cancer J. Sci. Am. 4:62.
49. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
50. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.